DexCom, Inc. (NASDAQ:DXCM) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of DexCom, Inc. (NASDAQ:DXCM) have been given a consensus recommendation of “Moderate Buy” by the twenty-seven ratings firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, three have given a hold rating, twenty-one have assigned a buy rating and two have issued a strong buy rating on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $84.88.

Several equities analysts have recently weighed in on the company. Weiss Ratings reissued a “hold (c-)” rating on shares of DexCom in a report on Monday, June 1st. TD Cowen reissued a “buy” rating and set a $95.00 price target (up from $75.00) on shares of DexCom in a report on Wednesday, June 10th. Stifel Nicolaus set a $90.00 price objective on DexCom and gave the stock a “buy” rating in a research note on Friday, June 5th. Raymond James Financial restated a “strong-buy” rating and issued a $91.00 price objective on shares of DexCom in a research note on Monday, June 8th. Finally, Canaccord Genuity Group set a $82.00 price objective on DexCom and gave the stock a “buy” rating in a research note on Monday, May 18th.

DexCom Stock Performance

DXCM stock opened at $68.94 on Wednesday. The stock’s 50 day simple moving average is $67.23 and its 200 day simple moving average is $68.01. The stock has a market capitalization of $26.60 billion, a PE ratio of 29.46, a price-to-earnings-growth ratio of 1.08 and a beta of 1.45. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42. DexCom has a 12-month low of $54.11 and a 12-month high of $89.98.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.09. The firm had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.17 billion. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The company’s revenue was up 15.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.32 EPS. As a group, research analysts forecast that DexCom will post 2.58 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other DexCom news, Director Mark G. Foletta sold 4,000 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $74.13, for a total value of $296,520.00. Following the completion of the sale, the director owned 52,852 shares in the company, valued at approximately $3,917,918.76. This represents a 7.04% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,759 shares of the firm’s stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $72.00, for a total value of $1,926,648.00. Following the transaction, the insider owned 382,482 shares of the company’s stock, valued at approximately $27,538,704. The trade was a 6.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 46,694 shares of company stock worth $3,343,977 in the last three months. 0.28% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Brighton Jones LLC lifted its stake in DexCom by 257.7% in the fourth quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock worth $1,290,000 after purchasing an additional 11,946 shares during the last quarter. Integrated Wealth Concepts LLC raised its stake in shares of DexCom by 6.3% during the first quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock valued at $227,000 after acquiring an additional 196 shares in the last quarter. Empowered Funds LLC raised its stake in shares of DexCom by 5.4% during the first quarter. Empowered Funds LLC now owns 8,446 shares of the medical device company’s stock valued at $577,000 after acquiring an additional 436 shares in the last quarter. Focus Partners Wealth raised its stake in shares of DexCom by 13.2% during the first quarter. Focus Partners Wealth now owns 7,218 shares of the medical device company’s stock valued at $493,000 after acquiring an additional 841 shares in the last quarter. Finally, NewEdge Advisors LLC raised its stake in shares of DexCom by 1.4% during the second quarter. NewEdge Advisors LLC now owns 19,253 shares of the medical device company’s stock valued at $1,681,000 after acquiring an additional 258 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.